Recombinant protein · Protein replacement · developed by Genzyme
Alglucosidase alfa is a recombinant lysosomal enzyme that provides an exogenous source of acid alpha-glucosidase (GAA). It is taken up through mannose-6-phosphate receptors into lysosomes, where it cleaves glycogen. It is studied in glycogen storage disease type II (Pompe disease).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 10, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04848779 | N/A | Glycogen Storage Disease Type II | Completed | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glycogen Storage Disease Type II
Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →